世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000029104

中国における医療、規制、および医療費償還制度の展望

GlobalData

China - Healthcare, Regulatory and Reimbursement Landscape

発刊日 2021/03/15

言語英語

体裁PDF/159ページ

ライセンス/価格159ページ

0000029104

PDF版 1,995USD

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。他のライセンス形態・価格に関しましてはご相談下さい。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

本レポートは、中国における医療、規制、および医療費償還制度の展望に関する情報や分析に不可欠な情報を提供し、医療市場における主要動向を明らかにします。また、人口動態、規制、医療費償還制度の展望、および医療インフラに関する見識を提供します。さらに、製薬および医療機器市場の動向やセグメントに関する貴重な情報を提供します。

最も重要なこととして、本レポートは、製薬および医療機器市場のトレンドとセグメンテーションに対する貴重な洞察を提供します。GlobalData社の業界専門家チームによる独自のデータベース、二次調査、社内分析からのデータと情報を使用して構築されています。

中国の医薬品業界は、2012年に7,201億ドルと評価され、2018年には1,346億ドルまで成長しました。2025年には年平均成長率(CAGR)12.2%で3,009億ドルに達すると予想されています。高齢者人口の増加、社会医療保険の拡大、イノベーションと承認タイムラインの最短化を目的とした規制改革などが、中国の医薬品市場の成長を促進する要因となっています。中国の医療機器市場は、2015年に286億ドルでしたが、2019年には352億ドルに増加し、年平均成長率は5.36%となりました。2021年からはCAGR5.90%で成長し、2025年には494億ドルに達すると予想されています。中国の第14次5カ年計画(2021-2025)と「メイド・イン・チャイナ(MIC)2025」構想は、イノベーションを強化し、効率的な国内サプライチェーンを発展させ、中国を「製造業大国」に変えることを目的としています。

■調査範囲

  • 市場規模、市場セグメント、主要推進要因、および障壁など、中国における製薬および医療機器市場の概説
  • 主要企業のプロファイルとSWOT分析
    ➣ 主要製薬企業:Pfizer、Novartis、Sinopharm、Jiangsu Hengrui Medicine、Beijing Tong Ren Tang
    ➣ 主要医療機器企業:Abbott、Medtronic、Roche Diagnostics、Boston Scientific,、Shinva
  • COVID-19疫学、COVID-19の影響とヘルスケア市場の進展、HealthTech展望、償還と規制展望に関する洞察に富んだレビュー、国のヘルスケア償還プロセス、規制当局、新薬と医療機器の承認プロセスの詳細をカバーする分析
  • ヘルスケア償還プロセス、規制機関、新薬および医療機器の承認プロセスの詳細を含む、償還および規制状況の洞察を深めたレビュー
  • 最近の医療政策、医療インフラおよび医療費に関する情報
  • 中国の医療市場における成長の機会と成長の課題の概要

レポート詳細

目次

1. Table of Contents
1.1List of Figures
1.2 LIST OF TABLES

2. Executive Summary
2.1 Executive Summary
2.2 Key Highlights: Facts about the Chinese Healthcare Market
2.3 Key Highlights: Healthcare Startups in China
2.4 Key Events: Chinese Healthcare Timeline, 2015-2021
2.5 Key Events: Facts About the Chinese Pharmaceutical Market
2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2019-2020
2.7 Key Events: Top Completed Deals by Value, 2019-2020
2.8 Country Profile, China, 2020

3. Overview of Pharmaceutical Market
3.1 Pharmaceutical Market - Overview
3.2 Pharmaceutical Market - Exports
3.3 Pharmaceutical Market - Imports
3.4 Pharmaceutical Market - Supply Channels, China
3.5 Pharmaceutical Market - Market Segments
3.6 Pharmaceutical Market - Market Segment, Generics, China
3.7 Pharmaceutical Market - Market Segment, Biologics and Biosimilars, China
3.8 Pharmaceutical Market - Market Segment, Over-the-Counter Medicines, China
3.9 Pharmaceutical Market - Market Segment, Traditional Chinese Medicines, China
3.10 Pharmaceutical Market - Market Segment, Cell and Gene Therapy, China
3.11 COVID-19 Epidemiology, China
3.12 COVID-19 Impact and Developments in the Healthcare Market, China
3.13 COVID-19 Clinical Trials Landscape, China
3.14 Major Therapeutic Areas, China
3.15 Pharmaceutical Market - Major Players

4. Overview of Medical Devices Market
4.1 Medical Device Market - Overview
4.2 Medical Devices Market - Major Players

5. Pharmaceutical and Medical Devices Market - Drivers and Barriers
5.1 Drivers
5.2 Barriers

6. Deal Analysis
6.1 Deal Analysis: Pharmaceutical Market, China, 2020-2021
6.2Deal Analysis: Medical Devices Market, China, 2020-2021

7. HealthTech Landscape
7.1 HealthTech Deals Landscape, China
7.2 Key HealthTech Deals, China
7.3 Adoption of Technology in Healthcare, China
7.4 Regulatory Scenario Covering Use of Technology in Healthcare, China
7.5 HealthTech Landscape: Benefits and Risks, China

8. Market Access
8.1 Overview of Healthcare System, China
8.2 Reimbursement Process, China
8.3 Overview of Insurance Providers, China
8.4 Out-of-Pocket Spending and Consumer Price Index, China
8.5 Pricing Policies, China
8.6 Regulatory Landscape, China
8.6.1 Overview of Regulatory Agencies
8.7 Marketing Authorization for Pharmaceutical Products, China
8.8 Marketing Authorization for Generic Drugs, China
8.9 Market Authorization for Medical Devices, China
8.10 Intellectual Property Rights, Patent, China
8.11 Intellectual Property Rights, Trademark, China
8.12 Pharmaceutical Clinical Trials Landscape, China
8.13 Medical Devices Clinical Trials Landscape, China
8.14 Pharmaceutical Advertisement Regulations, China
8.15 Labeling and Packaging Regulations, China

9. Country Healthcare Landscape
9.1 Healthcare Policy Highlights, China
9.2 Healthcare Facilities, China
9.3 Life Expectancy and Immunization Rate, China
9.4 Environmental Health, China
9.5 Healthcare Personnel, China
9.6 Disease Burden, China
9.7 Healthcare Expenditure, China
9.8 Pharmaceutical R&D Expenditure, China

10 Trade Associations, China

11 Trade Fairs, China

12 Opportunities and Challenges

13 Appendix
13.1 Research Methodology
13.1.1 Coverage
13.1.2 Secondary Research
13.1.3 Forecasts
13.2 Bibliography
13.3 About GlobalData
13.4 Contact Us
13.5 Disclaimer

List of Tables
Table 1: Domestic Companies Dominating Chinese Biosimilar Market, China, 2020
Table 2: NMPA-Approved New Drugs of Local Companies, China, 2020 (Jun’20-Dec’20)
Table 3: NMPA-Approved New Drugs of International Companies, China, 2020 (Aug’20-Dec’20)
Table 4: COVID-19 Indicators (Number of Cases), Global and China, 2020
Table 5: COVID-19 Marketed IVD Products (Oct ‘20 to Jan ‘21), China, 2021
Table 6: COVID-19 IVD Pipeline Products (In Approval Process), China, 2021
Table 7: Top Ten Therapeutic Areas by Morbidity Rate (1/100,000), China, 2019
Table 8: Medical Device Market, China, Major Segments ($M), 2020
Table 9: In Vitro Diagnostics Market, China, Revenue ($M) and Market Share (%) of Major Companies, 2018
Table 10: General Surgery Market, China, Revenue ($M) and Market Share (%) of Major Companies, 2019
Table 11: Orthopedic Devices Market, China, Revenue ($M) and Market Share (%) of Major Companies, 2019
Table 12: Cardiovascular Devices Market, China, Revenue ($M) and Market Share (%) of Major Companies, 2019
Table 13: Wound Care Management Market, China, Revenue ($M) and Market Share (%) of Major Companies, 2019
Table 14: Public Insurance Schemes, China, 2020
Table 15:Drug Classification System, China, 2020
Table 16: Medical Devices Classification, China, 2020
Table 17: Trademark Process Timeline, China, 2020
Table 18: Trade Fairs, China, 2020

List of Figures
Figure 1: Pharmaceutical Market, China, Revenue ($B), 2012-2020
Figure 2: Medical Devices Market, China, Revenue ($B), 2015-2020
Figure 3: Healthcare Startups in China, 2020
Figure 4: Number of Deals (2019-2020)
Figure 5: 2019-2020 Deal Overview by Region
Figure 6: Country Profile, China, 2020
Figure 7: Pharmaceutical Market, China, Revenue ($B), 2011-2018
Figure 8: Pharmaceutical Market, China, Revenue Forecast ($B), 2019-2025
Figure 9: Pharmaceutical Exports ($B), China, 2010-2019
Figure 10: Top Export Partners, China, 2019
Figure 11: Pharmaceutical Imports ($B), China, 2010-2019
Figure 12: Top Import Partners, China, 2019
Figure 13: Pharmaceutical Supply Channel, China, 2019
Figure 14: Pharmaceutical Drug Sales Channel, China, 2019
Figure 15: Supply Channel Prior to 2017, China, 2019
Figure 16: Two Invoice System, China, 2019
Figure 17: Approval of Category 1 Innovative Products, China, 2015-2019
Figure 18: OTC Market, China, Revenue ($B), 2011-2020
Figure 19: OTC Medicines Market, Major Categories ($B), China, 2020
Figure 20: OTC Medicines Market, Major Distribution Channels ($M), China, 2020
Figure 21: Traditional Medicines, Revenue ($B), China, 2011-2020
Figure 22: Traditional Medicines, Per Capita Expenditure ($), China, 2011-2020
Figure 23: COVID-19 (Cases), China, 2020
Figure 24: COVID-19 (Deaths), China, 2020
Figure 25: Timeline of Facts & Control Measures During COVID-19 Epidemic, China, Dec ‘19 - Feb ’20
Figure 26: NMPA-approved Drug Applications Amid COVID-19 Epidemic, China, Q1 2019-Q1 2020
Figure 27: NMPA-approved Drug Applications Amid COVID-19 Epidemic, China, 2020
Figure 28: COVID-19 Clinical Trials Count By Trial Status, China, 2020
Figure 29: COVID-19 Clinical Trials Count By Phase, China, 2020
Figure 30: Top Five COVID-19 Clinical Trials Sponsors By Count, China, 2020
Figure 31: Top Five Therapeutic Areas by Morbidity Rate (%), China, 2019
Figure 32: Medical Device Market, China, Revenue ($B), 2015-2020
Figure 33: Medical Device Market, China, Revenue Forecast ($B), 2021-2025
Figure 34: Medical Device Market, China, Major Segments (%), 2020
Figure 35: In Vitro Diagnostics Market, China, Revenue ($B), 2017-2025
Figure 36: In Vitro Diagnostics Market, China, Market Share of Major Players (%), 2019
Figure 37: General Surgery Market, China, Revenue ($M), 2015-2022
Figure 38: General Surgery Market, China, Market Share of Major Players (%), 2019
Figure 39: Orthopedic Devices Market, China, Revenue ($B), 2017-2025
Figure 40: Orthopedic Devices Market, China, Market Share of Major Players (%), 2019
Figure 41: Cardiovascular Devices Market, China, Revenue ($B), 2017-2025
Figure 42: Cardiovascular Devices Market, China, Market Share of Major Players (%), 2019
Figure 43: Wound Care Management Market, China, Revenue ($B), 2017-2025
Figure 44: Wound Care Management Market, China, Market Share of Major Players (%), 2019
Figure 45: Diagnostic Market, China, Revenue ($B), 2015-2020
Figure 46: Diagnostic Market, China, Revenue ($B), 2021-2025
Figure 47: Medical Devices Market, Revenue ($B) of Major Companies, China, 2019
Figure 48: Deal Value and Deal Count, Pharmaceutical Market, China, 2020-2021
Figure 49: Deal Value and Deal Count Sub-types, Pharmaceutical Market, China, 2020-2021
Figure 50: Deal Value and Deal Count, Quarterly, Pharmaceutical Market, China, 2020-2021
Figure 51: Top Five Therapy Areas by Deal Value ($M), Pharmaceutical Market, China, 2020-2021
Figure 52: Top Five Therapy Areas by Deal Number, Pharmaceutical Market, China, 2020-2021

この商品のレポートナンバー

0000029104

TOP